153 related articles for article (PubMed ID: 18379370)
1. Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.
Wu SG; Shih JY; Yu CJ; Yang PC
J Thorac Oncol; 2008 Apr; 3(4):451-2. PubMed ID: 18379370
[No Abstract] [Full Text] [Related]
2. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Pennell NA; Yin L; Keshtgarpour M; Ma PC
J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
[No Abstract] [Full Text] [Related]
3. An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.
Chan AW; Tong JH; Lo SH; To KF
J Thorac Oncol; 2013 Dec; 8(12):e107-8. PubMed ID: 24389445
[No Abstract] [Full Text] [Related]
4. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
5. First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
Le Maignan L; Mirebeau-Prunier D; Vervueren L; Jeanfaivre T; Urban T; Hureaux J
J Thorac Oncol; 2011 Mar; 6(3):639-40. PubMed ID: 21317745
[No Abstract] [Full Text] [Related]
6. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
7. A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.
Nakamura T; Sueoka-Aragane N; Iwanaga K; Sato A; Komiya K; Abe T; Ureshino N; Hayashi S; Hosomi T; Hirai M; Sueoka E; Kimura S
J Thorac Oncol; 2011 Oct; 6(10):1639-48. PubMed ID: 21921847
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Katayama T; Shimizu J; Suda K; Onozato R; Fukui T; Ito S; Hatooka S; Sueda T; Hida T; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Nov; 4(11):1415-9. PubMed ID: 19692934
[TBL] [Abstract][Full Text] [Related]
9. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
[TBL] [Abstract][Full Text] [Related]
10. Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
Hirai F; Takenoyama M; Taguchi K; Toyozawa R; Inamasu E; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Ushijima C; Seto T; Takeo S; Ichinose Y
J Thorac Oncol; 2014 May; 9(5):e37-9. PubMed ID: 24722163
[No Abstract] [Full Text] [Related]
11. Two rare exon 21 EGFR mutations in patients treated with gefitinib.
Mompradé E; Arriola E; Martínez-Avilés L
J Thorac Oncol; 2013 Apr; 8(4):e36-7. PubMed ID: 23486275
[No Abstract] [Full Text] [Related]
12. Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.
Fallet V; Ruppert AM; Poulot V; Lacave R; Belmont L; Antoine M; Cadranel J; Wislez M; Lavolé A
J Thorac Oncol; 2012 Jun; 7(6):1061-3. PubMed ID: 22588159
[No Abstract] [Full Text] [Related]
13. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664
[TBL] [Abstract][Full Text] [Related]
14. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
Wong AS; Soong R; Seah SB; Lim SW; Chuah KL; Nga ME; Chin TM; Soo RA
J Thorac Oncol; 2008 Apr; 3(4):400-4. PubMed ID: 18379359
[TBL] [Abstract][Full Text] [Related]
15. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.
Popat S; Vieira de Araújo A; Min T; Swansbury J; Dainton M; Wotherspoon A; Lim E; Nicholson AG; O'Brien ME
J Thorac Oncol; 2011 Nov; 6(11):1962-3. PubMed ID: 22005476
[No Abstract] [Full Text] [Related]
16. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Koyama N; Uchida Y
Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
[TBL] [Abstract][Full Text] [Related]
17. EGFR exon 19 insertions show good response to gefitinib, but short time to progression in Japanese patients.
Park J; Kondo C; Shimizu J; Horio Y; Yoshida K; Hida T
J Thorac Oncol; 2014 Feb; 9(2):e10-1. PubMed ID: 24419426
[No Abstract] [Full Text] [Related]
18. Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.
Lee CN; Chen HY; Liu HE
J Clin Oncol; 2010 Mar; 28(7):e111-2. PubMed ID: 20008635
[No Abstract] [Full Text] [Related]
19. Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.
Gow CH; Shih JY; Chang YL; Yu CJ
PLoS Med; 2005 Sep; 2(9):e269. PubMed ID: 16173832
[No Abstract] [Full Text] [Related]
20. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
